Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tika R. Malla

Tika R. Malla

Contact information

Email
tika.malla@cmd.ox.ac.uk

Research groups

The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI)

Tika R. Malla

DPhil

Postdoctoral Scientist - Enzymology and Assay Development

Recent publications

RaPID discovery of cell-permeable helical peptide inhibitors con-taining cyclic β-amino acids against SARS-CoV-2 main protease.

Kawai M. et al, (2025), RSC Chem Biol, 6, 1089 - 1099

Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease.

Miura T. et al, (2024), Bull Chem Soc Jpn, 97

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Boby ML. et al, (2023), Science, 382

In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease.

Miura T. et al, (2023), Nat Chem, 15, 998 - 1005

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Chenthamarakshan V. et al, (2023), Sci Adv, 9

More publications